CR11396A - Nuevos anticuerpos especificos de los peptidos-b-amiloides y sus usos como agentes de diagnostico o drogas - Google Patents

Nuevos anticuerpos especificos de los peptidos-b-amiloides y sus usos como agentes de diagnostico o drogas

Info

Publication number
CR11396A
CR11396A CR11396A CR11396A CR11396A CR 11396 A CR11396 A CR 11396A CR 11396 A CR11396 A CR 11396A CR 11396 A CR11396 A CR 11396A CR 11396 A CR11396 A CR 11396A
Authority
CR
Costa Rica
Prior art keywords
peptides
amylooids
diagnostic
specific antibodies
new specific
Prior art date
Application number
CR11396A
Other languages
English (en)
Inventor
Eugeen Vanmechelen
Pierre Grognet
Nicolas Sergeant
Marie Gompel
Andre Delacourte
Luc Buee
Laurent Pradier
Veronique Blanchard-Bregeon
Original Assignee
Inst Nat Sante Rech Med
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38925731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR11396(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inst Nat Sante Rech Med, Sanofi Aventis filed Critical Inst Nat Sante Rech Med
Publication of CR11396A publication Critical patent/CR11396A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a un anticuerpo monoclonal que se une específicamente a la región N-terminal de péptidos AB8-x, estando x comprendido desde 11 a 42, y que no reconoce ni AB1-40 ni AB1-42 y que presenta una elevada afinidad con respecto a péptidos AB8-x, tal como se determina mediante la formación de complejo inmunológico entre el anticuerpo monoclonal y el péptido AB8-x.
CR11396A 2007-10-29 2010-04-28 Nuevos anticuerpos especificos de los peptidos-b-amiloides y sus usos como agentes de diagnostico o drogas CR11396A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07119537 2007-10-29

Publications (1)

Publication Number Publication Date
CR11396A true CR11396A (es) 2012-10-18

Family

ID=38925731

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11396A CR11396A (es) 2007-10-29 2010-04-28 Nuevos anticuerpos especificos de los peptidos-b-amiloides y sus usos como agentes de diagnostico o drogas

Country Status (27)

Country Link
US (1) US8343493B2 (es)
EP (1) EP2205633A1 (es)
JP (1) JP5421277B2 (es)
KR (1) KR20100097651A (es)
CN (1) CN101883792B (es)
AP (1) AP2957A (es)
AR (1) AR069085A1 (es)
AU (1) AU2008317705B2 (es)
CA (1) CA2703825A1 (es)
CL (1) CL2008003197A1 (es)
CO (1) CO6270369A2 (es)
CR (1) CR11396A (es)
EA (1) EA201070539A1 (es)
EC (1) ECSP10010142A (es)
HN (1) HN2010000880A (es)
IL (1) IL205398A0 (es)
MA (1) MA31793B1 (es)
MX (1) MX2010004660A (es)
MY (1) MY155144A (es)
NI (1) NI201000075A (es)
NZ (1) NZ585000A (es)
TN (1) TN2010000197A1 (es)
TW (1) TW200936605A (es)
UA (1) UA103602C2 (es)
UY (1) UY31433A1 (es)
WO (1) WO2009056490A1 (es)
ZA (1) ZA201002989B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2674140C (en) * 2007-01-05 2018-05-15 University Of Zurich Method of providing disease-specific binding molecules and targets
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
KR101781228B1 (ko) 2008-12-19 2017-09-22 바이오겐 인터내셔널 뉴로사이언스 게엠베하 인간 항-알파-시누클레인 자가항체
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
US8337845B2 (en) 2010-03-03 2012-12-25 Boehringer Ingelheim International Gmbh A-beta binding polypeptides
EP2511296A1 (en) * 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
MX357193B (es) 2011-06-23 2018-06-29 Univ Zuerich Moleculas de union anti-alfa sinucleina.
WO2013167681A1 (en) 2012-05-10 2013-11-14 Georg-August-Universität Göttingen CONFORMATIONAL-SPECIFIC ANTIBODIES AGAINST Αβ OLIGOMERS
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
US10774120B2 (en) * 2015-11-09 2020-09-15 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
JP2019533426A (ja) 2016-07-18 2019-11-21 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータに対する抗体
WO2018017754A1 (en) 2016-07-19 2018-01-25 Duke University Therapeutic applications of cpf1-based genome editing
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
CN118370815A (zh) 2017-08-22 2024-07-23 渤健马萨诸塞州股份有限公司 含有抗β淀粉样蛋白抗体的药物组合物
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
EP3861023A1 (en) 2018-10-04 2021-08-11 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Humanised anti-n-truncated amyloid beta monoclonal antibody
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
CA3185040A1 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
EP4448564A1 (en) * 2021-12-17 2024-10-23 F. Hoffmann-La Roche AG A novel antibody for detection of amyloid beta 42 (a-beta42)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2487528A1 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung

Also Published As

Publication number Publication date
ZA201002989B (en) 2011-07-27
CO6270369A2 (es) 2011-04-20
AP2010005249A0 (en) 2010-06-30
WO2009056490A1 (en) 2009-05-07
TW200936605A (en) 2009-09-01
JP2011502139A (ja) 2011-01-20
MX2010004660A (es) 2010-07-30
UA103602C2 (ru) 2013-11-11
EP2205633A1 (en) 2010-07-14
MY155144A (en) 2015-09-15
CN101883792A (zh) 2010-11-10
NZ585000A (en) 2012-08-31
AR069085A1 (es) 2009-12-30
TN2010000197A1 (en) 2011-11-11
KR20100097651A (ko) 2010-09-03
AU2008317705B2 (en) 2014-06-05
EA201070539A1 (ru) 2010-10-29
HN2010000880A (es) 2014-03-10
ECSP10010142A (es) 2010-07-30
NI201000075A (es) 2010-09-23
CL2008003197A1 (es) 2010-01-15
IL205398A0 (en) 2010-12-30
UY31433A1 (es) 2009-05-29
JP5421277B2 (ja) 2014-02-19
CN101883792B (zh) 2014-08-27
US8343493B2 (en) 2013-01-01
MA31793B1 (fr) 2010-10-01
AP2957A (en) 2014-08-31
AU2008317705A1 (en) 2009-05-07
US20110059092A1 (en) 2011-03-10
CA2703825A1 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
CR11396A (es) Nuevos anticuerpos especificos de los peptidos-b-amiloides y sus usos como agentes de diagnostico o drogas
MX2020001752A (es) Anticuerpos anti-cd3 y metodos de uso.
CL2019000100A1 (es) Anticuerpos contra tim3 y suso de los mismos.
MX377605B (es) Inmunoglobulina híbrida conteniendo un enlace no-peptidílico.
AR101846A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
PE20090329A1 (es) Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
MX384225B (es) ANTICUERPOS IgG BIESPECIFICOS, ACOPLADORES DE LINFOCITOS T.
MX2021013586A (es) Anticuerpo monoclonal anti-antigeno 4 asociado a linfocitos t citotoxicos (ctla4) o su fragmento de union a antigeno, una composicion farmaceutica y uso.
AR080795A1 (es) Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
PE20140806A1 (es) Anticuerpos anti-factor d humanizados y sus usos
CO6710903A2 (es) Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo
SG178886A1 (en) Humanized anti-cdcp1 antibodies
PE20251579A1 (es) Anticuerpos especificos para cd70 y sus usos
CR11374A (es) Proteinas humanas de union a antigenos del gm-csf
CR20120127A (es) Anticuerpos monoclonales
AR091961A1 (es) Inmunoconjugados y anticuerpos anti-etbr (receptor de endotelina b)
CL2021000736A1 (es) Receptor de antígeno quimérico.
MX2015008740A (es) Variantes de regiones fc de igg1 de humano y usos de las mismas.
ECSP14013307A (es) Genzyme corporation
MX2018003410A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
AR095432A1 (es) Proteínas de unión a antígeno
MX2013007371A (es) Peptidos de enlace her2 radiomarcados.
MX2020004674A (es) Anticuerpos contra alfa-sinucleina y usos de los mismos.
UA113879C2 (xx) ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ
UA117097C2 (uk) Антитіло проти лігандів рецептора в1 брадикініну